KM
Therapeutic Areas
Vanda Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| HETLIOZ® (tasimelteon) | Non-24-Hour Sleep-Wake Disorder | Marketed |
| Fanapt® (iloperidone) | Schizophrenia (oral) | Marketed |
| BYSANTI™ (milsaperidone) | Bipolar I Disorder & Schizophrenia | Marketed |
| NEREUS™ (tradipitant) | Atopic Dermatitis | Development |
| PONVORY® (ponesimod) | Multiple Sclerosis | Marketed |
| Imsidolimab | Generalized Pustular Psoriasis (GPP) | BLA Filed |
| Trichostatin A (TSA) | Hematologic Malignancies | Development |
Leadership Team at Vanda Pharmaceuticals
MH
Mihael H. Polymeropoulos, MD
President, Chief Executive Officer and Chairman of the Board
TW
Tim Williams
Senior Vice President, General Counsel and Secretary
JW
Joakim Wijkstrom
Senior Vice President, Chief Marketing Officer
GB
Gunther Birznieks
Senior Vice President, Business Development
DP
Deepak Phadke, PhD
Vice President of Manufacturing
SH
Scott Howell
Chief People Officer
RW
Richard W. Dugan
Lead Independent Director
SR
Stephen Ray Mitchell, MD, M.B.A.
Director
PC
Phaedra Chrousos
Director
AS
Anne Sempowski Ward
Director